Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

Analyst Derek Archila of Wells Fargo assigned a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), retaining the price ...

The CHMP initially adopted a negative opinion in January after finding it was unable to establish a positive balance of benefits and risks for Syfovre, but Apellis sought a re-examination and was able ...

Bank of America Securities analyst Tazeen Ahmad has maintained their bullish stance on APLS stock, giving a Buy rating yesterday. Tazeen Ahmad ...

The decision against Syfovre’s approval follows efforts by Apellis to have reviewers reevaluate clinical evidence multiple times and, according to an analyst, will lead to a restructuring of the ...

Apellis Pharmaceuticals shares are moving lower after the Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its June 2024 negative opinion following ...

Ginkgo Bioworks is pivoting: Once a synthetic biology darling, the flailing company has now turned to AI-driven protein ...

Apellis Pharmaceuticals Inc (APLS) stock saw a modest uptick, ending the day at $36.73 which represents a slight increase of $1.10 or 3.09% from the prior close of $35.63. The stock opened at $36.24 ...

European regulators on Friday upheld its negative opinion on Apellis Pharmaceuticals' (NASDAQ:APLS) proposed treatment for ...

European regulators rejected Apellis Pharmaceuticals' embattled eye drug, Syfovre, and Apellis stock tumbled to a month-low.

Mizuho has reiterated its Neutral rating on Apellis Pharmaceuticals (NASDAQ: NASDAQ:APLS) with a steady price target of $42.00. The firm's stance comes ahead of the European Medicines Agency's ...

Detailed price information for British Pound/Sudanese Dinar (GBPSDD) from The Globe and Mail including charting and trades.